Takeda Pharmaceutical Co. Ltd. ADR (TAK): Price and Financial Metrics


Takeda Pharmaceutical Co. Ltd. ADR (TAK): $14.58

-0.24 (-1.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TAK POWR Grades

  • Value is the dimension where TAK ranks best; there it ranks ahead of 97.04% of US stocks.
  • The strongest trend for TAK is in Growth, which has been heading up over the past 178 days.
  • TAK ranks lowest in Momentum; there it ranks in the 12th percentile.

TAK Stock Summary

  • Price to trailing twelve month operating cash flow for TAK is currently 0.04, higher than just 1% of US stocks with positive operating cash flow.
  • In terms of volatility of its share price, TAK is more volatile than only 2.88% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TAK comes in at 1,151.93% -- higher than that of 99.56% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to TAKEDA PHARMACEUTICAL CO LTD, a group of peers worth examining would be PCAR, CNHI, STLA, DD, and TEL.
  • Visit TAK's SEC page to see the company's official filings. To visit the company's web site, go to www.takeda.com.

TAK Stock Price Chart Interactive Chart >

Price chart for TAK

TAK Price/Volume Stats

Current price $14.58 52-week high $15.36
Prev. close $14.82 52-week low $12.28
Day low $14.57 Volume 3,128,870
Day high $14.71 Avg. volume 2,757,166
50-day MA $13.42 Dividend yield 1.89%
200-day MA $14.06 Market Cap 45.21B

Takeda Pharmaceutical Co. Ltd. ADR (TAK) Company Bio


The Takeda Pharmaceutical Company Limited (武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha[takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neurosciencegastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-kuOsaka, and it has an office in NihonbashiChuoTokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. (Source:Wikipedia)


TAK Latest News Stream


Event/Time News Detail
Loading, please wait...

TAK Latest Social Stream


Loading social stream, please wait...

View Full TAK Social Stream

Latest TAK News From Around the Web

Below are the latest news stories about TAKEDA PHARMACEUTICAL CO LTD that investors may wish to consider to help them evaluate TAK as an investment opportunity.

Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease

Arrowhead provided a bullish update for its midstage liver disease treatment on Monday, pushing ARWR stock to rocket Tuesday.

Yahoo | November 29, 2022

Takeda's Dengue Vaccine Candidate Under FDA Priority Review

The FDA has accepted and granted priority review to Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Biologics License Application (BLA) for TAK-003, the company's investigational dengue vaccine candidate. In the U.S., TAK-003 is being evaluated for the prevention of dengue disease caused by any dengue virus serotype in individuals four years through 60 years of age. Dengue is a mosquito-borne virus endemic in more than 125 countries. The TAK-003 application is supported by safety and efficacy data fr

Yahoo | November 23, 2022

Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration

OSAKA, Japan and CAMBRIDGE, Massachusetts, November 22, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review of the Biologics License Application (BLA) for TAK-003, the company’s investigational dengue vaccine candidate. In the U.S., TAK-003 is being evaluated for the prevention of dengue disease caused by any dengue virus serotype in individuals 4 years through 60 years of age.

Yahoo | November 22, 2022

Why Puma Biotechnology's Shares Jumped 20% on Monday

The biopharmaceutical company specializes in cancer therapies. Its stock got a boost on Monday when a Takeda Pharmaceutical (NYSE: TAK) candidate, ponatinib, hit its primary goal in a phase 3 clinical trial as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia. The blood cancer therapy works by slowing the activity of BCR-ABL1, a gene sequence found in an abnormal chromosome 22, often seen in people with certain types of leukemia.

Yahoo | November 21, 2022

Religious employees allegedly fired for not getting COVID-19 vaccine sue Massachusetts pharmaceutical company

Several religious employees of a Massachusetts pharmaceutical company, who claim they were fired for refusing COVID-19 vaccine have filed a lawsuit, led by Alex Jones' attorney.

Yahoo | November 19, 2022

Read More 'TAK' Stories Here

TAK Price Returns

1-mo 10.54%
3-mo 9.05%
6-mo 7.52%
1-year 8.08%
3-year -25.15%
5-year -42.18%
YTD 6.97%
2021 -23.58%
2020 -5.97%
2019 19.31%
2018 -40.08%
2017 36.91%

TAK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full TAK Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7219 seconds.